Versatile Cell Line Platform

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, August 2023
Volume 47
Issue 8

Sphere Fluidics’ Cyto-Mine is an automated cell line platform that is designed to enable screening of up to 40 million cells over the course of several hours.

Sphere Fluidics’ Cyto-Mine

Sphere Fluidics’ Cyto-Mine

Sphere Fluidics’ Cyto-Mine is an automated cell line platform that integrates single cell screening, sorting, dispensing, imaging, and clone verification into one solution. Intended for use in various research areas, including antibody discovery, cell-line development, cell engineering, and synthetic biology, the device uses a unique microfluidic picodroplet technology that is designed to enable screening of up to 40 million cells over the course of several hours.

Recent software updates to the Cyto-Mine have been made to ensure compliance with current good manufacturing practice regulations. These updates include 21 CFR Part 11, FDA’s regulation for electronic documentation and electronic signatures, and a full installation qualification/operation qualification package, which is intended to support quick and easy equipment qualification.

Sphere Fluidics

Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines episode 6
Behind the Headlines episode 5
Related Content